Track topics on Twitter Track topics that are important to you
David Solomon, chief executive of Silence Therapeutics PLC (LON:SLN), updates Proactive London's Andrew Scott on the progress of its lead candidate SLN124 which is being developed to treat iron overload disorders.
Solomon also elaborates on two other exciting assets in the portfolio - one of them being SLN360 which is being developed as a potential treatment for cardiovascular disease.
Original Article: Silence Therapeutics accelerating into the clinicNEXT ARTICLE
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Cardiology is a specialty of internal medicine. Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...